Epistasis in sporadic Alzheimer's disease

The traditional approach in case-control association studies, to evaluate candidate genes individually, either single markers or haplotypes, has had limited success. The multifactorial nature of complex diseases suggests the alternative of examining gene-gene interactions (epistasis) within biological networks. We have used synergy factor analysis to assess over 100 claims of epistasis in sporadic Alzheimer's disease (AD), in networks involving, e.g. cholesterol, beta-amyloid, inflammation and oxidative stress. We found 27 gene-gene interactions that were significantly associated with AD. In most of these the main effect of one of the genes was so small that it would probably have been missed by the traditional locus-by-locus approach. There are questions, however, about the quality of replication studies: about sample sizes, about homogeneity, characterization and matching of sample sets, and about the statistical methods commonly used to assess interactions. Meta-analyses could now be conducted of the four interactions that have been sufficiently replicated, all involving APOE4: ACT -17AA; BACE1 exon5 GG; IL6 -174C; BCHE K. Only that between BACE1 exon5 GG and APOE4 has so far been consistently replicated. We conclude that epistasis is a crucial feature of complex diseases, that its study is a promising approach to the genetics of AD and that larger and more rigorous studies are needed to establish interactions.

[1]  V. Haroutunian,et al.  Modulation by DLST of the genetic risk of Alzheimer's disease in a very elderly population , 1999, Annals of neurology.

[2]  M. Ilyas Kamboh,et al.  A4POE*4-associated Alzheimer's disease risk is modified by α1–antichymotrypsin polymorphism , 1995, Nature Genetics.

[3]  M. Mattson Pathways towards and away from Alzheimer's disease , 2004, Nature.

[4]  Bruno Derudas,et al.  Peroxisome Proliferator-activated Receptor α Activators Improve Insulin Sensitivity and Reduce Adiposity* , 2000, The Journal of Biological Chemistry.

[5]  Takashi Asada,et al.  Dynamin-binding protein gene on chromosome 10q is associated with late-onset Alzheimer's disease. , 2006, Human molecular genetics.

[6]  C. Mariani,et al.  Interaction between the APOE ɛ4 allele and the APH-1b c+651T>G SNP in Alzheimer's disease , 2008, Neurobiology of Aging.

[7]  E. Tolosa,et al.  α-Antichymotrypsin gene polymorphism and risk for Alzheimer's disease in the Spanish population , 1998, Neuroscience Letters.

[8]  R. Perry,et al.  Association studies of transforming growth factor‐β1 and Alzheimer's disease , 2005 .

[9]  F. Panza,et al.  Interleukin 6-174 G/C promoter gene polymorphism and sporadic Alzheimer's disease: geographic allele and genotype variations in Europe , 2004, Experimental Gerontology.

[10]  A. Pfeffer,et al.  CYP46: A risk factor for Alzheimer's disease or a coincidence? , 2005, Neuroscience Letters.

[11]  Gérard Siest,et al.  Myeloperoxidase G-463A polymorphism and Alzheimer's disease in the ApoEurope study , 2003, Neuroscience Letters.

[12]  M. Owen,et al.  Substantial linkage disequilibrium across the insulin-degrading enzyme locus but no association with late-onset Alzheimer's disease , 2001, Human Genetics.

[13]  Barbara Borroni,et al.  VEGF gene and phenotype relation with Alzheimer's disease and mild cognitive impairment. , 2006, Rejuvenation research.

[14]  V. Moskvina,et al.  Interaction between the ADAM12 and SH3MD1 genes may confer susceptibility to late‐onset Alzheimer's disease , 2007, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[15]  S. Duan,et al.  Insulin-degrading enzyme and Alzheimer disease , 2004, Neurology.

[16]  B. Strooper,et al.  Aph-1, Pen-2, and Nicastrin with Presenilin Generate an Active γ-Secretase Complex , 2003, Neuron.

[17]  M. Laakso,et al.  INTERLEUKIN-6 PROMOTER POLYMORPHISM AND LATE-ONSET ALZHEIMER's DISEASE IN THE FINNISH POPULATION , 2005, Journal of neurogenetics.

[18]  G. Perry,et al.  Book Review: Is Alzheimer’s Disease a Mitochondrial Disorder? , 2002, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[19]  H Jick,et al.  Statins and the risk of dementia , 2000, The Lancet.

[20]  L. Feuk,et al.  Variants of CYP46A1 may interact with age and APOE to influence CSF Aβ42 levels in Alzheimer’s disease , 2004, Human Genetics.

[21]  S. Sorbi,et al.  Absence of association between Alzheimer disease and the regulatory region polymorphism of the PS2 gene in an Italian population , 2003, Neuroscience Letters.

[22]  J. Nakura,et al.  The 4,752 C/T polymorphism in the presenilin 1 gene increases the risk of Alzheimer's disease in apolipoprotein E4 carriers. , 2002, Internal medicine.

[23]  J. Gilbert,et al.  Interaction between the α-T catenin gene (VR22) and APOE in Alzheimer’s disease , 2005, Journal of Medical Genetics.

[24]  S. McIlroy,et al.  Association of serum AACT levels and AACT signal polymorphism with late‐onset Alzheimer's disease in Northern Ireland , 2000, International journal of geriatric psychiatry.

[25]  Polymorphisms in cytoplasmic serine hydroxymethyltransferase and methylenetetrahydrofolate reductase affect the risk of cardiovascular disease in men. , 2005, The Journal of nutrition.

[26]  M. Xiong,et al.  A systems biology approach to genetic studies of complex diseases , 2005, FEBS letters.

[27]  W. Markesbery,et al.  Oxidized Low‐Density Lipoprotein Induces Neuronal Death , 1999, Journal of neurochemistry.

[28]  O. Combarros,et al.  Interaction between estrogen receptor-α and butyrylcholinesterase genes modulates Alzheimer’s disease risk , 2007, Journal of Neurology.

[29]  Rena Li,et al.  Microglia and inflammatory mechanisms in the clearance of amyloid β peptide , 2002 .

[30]  P. Mecocci,et al.  Interaction of CTSD and A2M polymorphisms in the risk for Alzheimer's disease , 2006, Journal of the Neurological Sciences.

[31]  Zhenxin Zhang,et al.  Association between Cathepsin D Polymorphism and Alzheimer’s Disease in a Chinese Han Population , 2004, Dementia and Geriatric Cognitive Disorders.

[32]  M. Imagawa,et al.  Deficiency in mitochondrial aldehyde dehydrogenase increases the risk for late-onset Alzheimer's disease in the Japanese population. , 2000, Biochemical and biophysical research communications.

[33]  J. Lambert,et al.  Association study of the vascular endothelial growth factor gene with the risk of developing Alzheimer's disease , 2006, Neurobiology of Aging.

[34]  D. Comas,et al.  Association study between Alzheimer’s disease and genes involved in Aβ biosynthesis, aggregation and degradation: suggestive results with BACE1 , 2003, Journal of Neurology.

[35]  E. Tangalos,et al.  Insulin degrading enzyme (IDE) genetic variants and risk of Alzheimer's disease: evidence of effect modification by apolipoprotein E (APOE) , 2003, Neuroscience Letters.

[36]  O. Combarros,et al.  Interaction between interleukin–6 and intercellular adhesion molecule–1 genes and Alzheimer’s disease risk , 2005, Journal of Neurology.

[37]  G. Forloni,et al.  Tumor necrosis factor α polymorphism C-850T is not associated with Alzheimer's disease and vascular dementia in an Italian population , 2003, Neuroscience Letters.

[38]  A. Hofman,et al.  Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. , 2001, The New England journal of medicine.

[39]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[40]  P. Passmore,et al.  Common polymorphisms in LRP and A2M do not affect genetic risk for Alzheimer disease in Northern Ireland. , 2001, American journal of medical genetics.

[41]  Ze Yang,et al.  Association between a T/C polymorphism in intron 2 of cholesterol 24S-hydroxylase gene and Alzheimer's disease in Chinese , 2004, Neuroscience Letters.

[42]  B. Hernández-Charro,et al.  El polimorfismo ACT/AA podría duplicar el riesgo de enfermedad de Alzheimer asociado al alelo APOE*ε4 , 2004 .

[43]  C. Carter,et al.  Convergence of genes implicated in Alzheimer's disease on the cerebral cholesterol shuttle: APP, cholesterol, lipoproteins, and atherosclerosis , 2007, Neurochemistry International.

[44]  M. Esiri,et al.  Accuracy of Clinical Operational Diagnostic Criteria for Alzheimer’s Disease in Relation to Different Pathological Diagnostic Protocols , 1998, Dementia and Geriatric Cognitive Disorders.

[45]  J. Haines,et al.  No Genetic Effect of α1-Antichymotrypsin in Alzheimer Disease , 1996 .

[46]  S. Humphries,et al.  The molecular genetics of cardiovascular disease: clinical implications , 2003, Journal of internal medicine.

[47]  P. Bosco,et al.  The CDC2 I-G-T haplotype associated with the APOE ɛ4 allele increases the risk of sporadic Alzheimer's disease in Sicily , 2007, Neuroscience Letters.

[48]  Longfei Jia,et al.  Genetic association between polymorphisms of Pen2 gene and late onset Alzheimer's disease in the North Chinese population , 2007, Brain Research.

[49]  A. Singleton,et al.  No association between the K variant of the butyrylcholinesterase gene and pathologically confirmed Alzheimer's disease. , 1998, Human molecular genetics.

[50]  A. Smith,et al.  Using meta-analysis to explain the diversity of results in genetic studies of late-onset Alzheimer’s disease and to identify high-risk subgroups , 2001, Neuroscience.

[51]  J. Haines,et al.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. , 1997, JAMA.

[52]  A. Smith,et al.  Synergy between the C2 allele of transferrin and the C282Y allele of the haemochromatosis gene (HFE) as risk factors for developing Alzheimer’s disease , 2004, Journal of Medical Genetics.

[53]  Lin He,et al.  An association study of the N-methyl-D-aspartate receptor NR1 subunit gene (GRIN1) and NR2B subunit gene (GRIN2B) in schizophrenia with universal DNA microarray , 2005, European Journal of Human Genetics.

[54]  O. Combarros,et al.  Interaction of the H63D Mutation in the Hemochromatosis Gene with the Apolipoprotein E Epsilon 4 Allele Modulates Age at Onset of Alzheimer’s Disease , 2003, Dementia and Geriatric Cognitive Disorders.

[55]  S. DeKosky,et al.  Genetic polymorphisms in the cathespin D and interleukin-6 genes and the risk of Alzheimer's disease , 2000, Neuroscience Letters.

[56]  Association of interleukin‐1 gene polymorphisms with Alzheimer's disease , 2000, Annals of neurology.

[57]  A. Smith,et al.  Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer's disease. , 1997, Human molecular genetics.

[58]  T. Ogihara,et al.  Low density lipoprotein receptor‐related protein gene polymorphisms and risk for late‐onset Alzheimer's disease in a Japanese population , 2000, Clinical genetics.

[59]  Xiongwei Zhu,et al.  Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's and other neurodegenerative diseases? , 2002, Free radical biology & medicine.

[60]  Y. Christen,et al.  Oxidative stress and Alzheimer disease. , 2000, The American journal of clinical nutrition.

[61]  D. Sparks,et al.  Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. , 2005, Archives of general psychiatry.

[62]  W. Maier,et al.  SREBP-1a Polymorphism Influences the Risk of Alzheimer’s Disease in Carriers of the ApoE4 Allele , 2004, Dementia and Geriatric Cognitive Disorders.

[63]  L. Lannfelt,et al.  A DLST genotype associated with reduced risk for Alzheimer’s disease , 1999, Neurology.

[64]  F. Rodríguez‐Artalejo,et al.  Alzheimer's risk associated with human apolipoprotein E, alpha-2 macroglobulin and lipoprotein receptor related protein polymorphisms: absence of genetic interactions, and modulation by gender , 2000, Neuroscience Letters.

[65]  J. Poirier Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease. , 2003, Trends in molecular medicine.

[66]  O. Combarros,et al.  Interaction between dopamine β-hydroxylase and interleukin genes increases Alzheimer’s disease risk , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[67]  Keith Hoots,et al.  Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS , 2002, Nature Genetics.

[68]  O. Combarros,et al.  Interaction between prion protein and interleukin-1A genes increases early-onset Alzheimer’s disease risk , 2007, Journal of Neurology.

[69]  E. Corder,et al.  Functional interaction between APOE4 and LDL receptor isoforms in Alzheimer’s disease , 2005, Journal of Medical Genetics.

[70]  O. Combarros,et al.  Interaction between CYP19 Aromatase and Butyrylcholinesterase Genes Increases Alzheimer’s Disease Risk , 2005, Dementia and Geriatric Cognitive Disorders.

[71]  M. Wade Epistasis, complex traits, and mapping genes. , 2001 .

[72]  J. Morris,et al.  Association studies using novel polymorphisms in BACE1 and BACE2 , 2001, Neuroreport.

[73]  R. Felder,et al.  Combinations of variations in multiple genes are associated with hypertension. , 2000, Hypertension.

[74]  Scott M. Williams,et al.  Traversing the conceptual divide between biological and statistical epistasis: systems biology and a more modern synthesis. , 2005, BioEssays : news and reviews in molecular, cellular and developmental biology.

[75]  F. Dudbridge,et al.  Functional genetic polymorphisms in cytokines and metabolic genes as additional genetic markers for susceptibility to develop type 1 diabetes , 2004, Genes and Immunity.

[76]  E. Sinforiani,et al.  Estrogen receptor α and APOEɛ4 polymorphisms interact to increase risk for sporadic AD in Italian females , 2006 .

[77]  A. Hofman,et al.  The α2-macroglobulin gene in AD , 2000, Neurology.

[78]  E. Gaetani,et al.  Proinflammatory Genetic Profiles in Subjects With History of Ischemic Stroke , 2004, Stroke.

[79]  J. Herz The LDL Receptor Gene Family (Un)Expected Signal Transducers in the Brain , 2001, Neuron.

[80]  F. Jessen,et al.  Gene‐gene interaction between interleukin‐6 and α2‐macroglobulin influences the risk for Alzheimer's disease , 2000 .

[81]  K. Morgan,et al.  Evaluation of polymorphisms in the presenilin-1 gene and the butyrylcholinesterase gene as risk factors in sporadic Alzheimer's disease , 1999, European Journal of Human Genetics.

[82]  P. Deyn,et al.  Association study of cholesterol-related genes in Alzheimer’s disease , 2007, Neurogenetics.

[83]  I. Simpson,et al.  Epistatic interaction between variations in the angiotensin I converting enzyme and angiotensin II type 1 receptor genes in relation to extent of coronary atherosclerosis , 2003, Heart.

[84]  Scott M. Williams,et al.  New strategies for identifying gene-gene interactions in hypertension , 2002, Annals of medicine.

[85]  R. Mayeux,et al.  Association studies of cholesterol metabolism genes (CH25H, ABCA1 and CH24H) in Alzheimer's disease , 2006, Neuroscience Letters.

[86]  H. Arai,et al.  α1-Antichymotrypsin gene polymorphism and risk for Alzheimer's disease , 2005, Journal of neural transmission.

[87]  R. Stewart,et al.  Assessment of association between mitochondrial aldehyde dehydrogenase polymorphism and Alzheimer’s disease in an older Korean population , 2004, Neurobiology of Aging.

[88]  N. Craddock,et al.  Polymorphism in AACT gene may lower age of onset of Alzheimer's disease , 1996, Neuroreport.

[89]  D. Allison,et al.  Detection of gene x gene interactions in genome-wide association studies of human population data. , 2007, Human heredity.

[90]  D. Mann,et al.  Silas Weir Mitchell and the “rest cure” , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[91]  O. Combarros,et al.  Cholesteryl ester transfer protein (CETP) polymorphism modifies the Alzheimer's disease risk associated with APOE ε4 allele , 2006, Journal of Neurology.

[92]  S. Poduslo,et al.  Genetic variants in brain-derived neurotrophic factor associated with Alzheimer’s disease , 2006, Journal of Medical Genetics.

[93]  A. Hofman,et al.  Polymorphisms in the interleukin 6 and transforming growth factor β1 gene and risk of dementia The Rotterdam Study , 2006, Neuroscience Letters.

[94]  P. S. St George-Hyslop,et al.  The gene encoding nicastrin, a major gamma-secretase component, modifies risk for familial early-onset Alzheimer disease in a Dutch population-based sample. , 2002, American journal of human genetics.

[95]  A. Padovani,et al.  Association analysis between anterior-pharynx defective-1 genes polymorphisms and Alzheimer's disease , 2003, Neuroscience Letters.

[96]  A. Fagan,et al.  Production and characterization of astrocyte-derived human apolipoprotein E isoforms from immortalized astrocytes and their interactions with amyloid-β , 2005, Neurobiology of Disease.

[97]  H. Feldman,et al.  Cholesterol in Alzheimer's disease , 2005, The Lancet Neurology.

[98]  J. Ioannidis,et al.  Replication validity of genetic association studies , 2001, Nature Genetics.

[99]  A. Weverling-Rijnsburger,et al.  Patients with Alzheimer's disease display a pro-inflammatory phenotype , 2001, Experimental Gerontology.

[100]  A. Mannermaa,et al.  MPO and APOEε4 polymorphisms interact to increase risk for AD in Finnish males , 2000, Neurology.

[101]  D. Feinstein,et al.  Noradrenergic regulation of inflammatory gene expression in brain , 2002, Neurochemistry International.

[102]  O. Combarros,et al.  Gene–gene interaction between interleukin-6 and interleukin-10 reduces AD risk , 2004, Neurology.

[103]  D. Galimberti,et al.  Vascular endothelial growth factor gene variability is associated with increased risk for AD , 2005, Annals of neurology.

[104]  J. H. Moore,et al.  Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. , 2001, American journal of human genetics.

[105]  O. Combarros,et al.  Genetic Association of CYP46 and Risk for Alzheimer’s Disease , 2004, Dementia and Geriatric Cognitive Disorders.

[106]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[107]  L. Polito,et al.  The urokinase-type plasminogen activator polymorphism PLAU_1 is a risk factor for APOE-ε4 non-carriers in the Italian Alzheimer’s disease population and does not affect the plasma Aβ(1–42) level , 2007, Neurobiology of Disease.

[108]  C. Geula,et al.  Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia , 1994, Annals of neurology.

[109]  J. Haines,et al.  Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis , 1997 .

[110]  F. Jessen,et al.  Confirmation of the association between bleomycin hydrolase genotype and Alzheimer's disease , 2000, Molecular Psychiatry.

[111]  E R Martin,et al.  Identification of significant association and gene-gene interaction of GABA receptor subunit genes in autism. , 2005, American journal of human genetics.

[112]  A. Ritchie,et al.  A new promoter polymorphism in the alpha-1-antichymotrypsin gene is a disease modifier of Alzheimer’s disease , 2005, Neurobiology of Aging.

[113]  T. Isobe,et al.  Processing of amyloid beta-peptides by neutral cysteine protease bleomycin hydrolase. , 2006, Protein and peptide letters.

[114]  A. Hofman,et al.  The cholesteryl ester transfer protein (CETP) gene and the risk of Alzheimer’s disease , 2007, Neurogenetics.

[115]  Zhenxin Zhang,et al.  Association of α2-macroglobulin polymorphisms and Alzheimer disease in Mainland Han Chinese , 2004, Journal of the Neurological Sciences.

[116]  C. Lukacs,et al.  Alzheimer’s Peptide Aβ1–42 Binds to Two β-Sheets of α1-Antichymotrypsin and Transforms It from Inhibitor to Substrate* , 1998, The Journal of Biological Chemistry.

[117]  W. Streit,et al.  Chemokines and Alzheimer’s disease , 2001, Neurobiology of Aging.

[118]  M. Gold,et al.  No interaction between the APOE and the alpha-1-antichymotrypsin genes on risk for Alzheimer's disease. , 1997, American journal of medical genetics.

[119]  Marylyn D. Ritchie,et al.  Multilocus Analysis of Hypertension: A Hierarchical Approach , 2004, Human Heredity.

[120]  J. Haines,et al.  Analysis of association between Alzheimer disease and the K variant of butyrylcholinesterase (BCHE-K) , 1999, Neuroscience Letters.

[121]  Y. Ohnishi,et al.  Association between a single-nucleotide polymorphism in the promoter of the human interleukin-3 gene and rheumatoid arthritis in Japanese patients, and maximum-likelihood estimation of combinatorial effect that two genetic loci have on susceptibility to the disease. , 2001, American journal of human genetics.

[122]  J. Emparanza,et al.  Genes related to iron metabolism and susceptibility to Alzheimer's disease in Basque population , 2007, Neurobiology of Aging.

[123]  H. Wiebusch,et al.  Further evidence for a synergistic association between APOEɛ4 and BCHE-K in confirmed Alzheimer’s disease , 1999, Human Genetics.

[124]  S. Antonarakis,et al.  Specific BACE1 genotypes provide additional risk for late‐onset alzheimer disease in APOE ε4 carriers , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[125]  O. Combarros,et al.  Association of genetic variants of ABCA1 with Alzheimer's disease risk , 2007, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[126]  F. Panza,et al.  Polymorphisms in the oxidized low-density lipoprotein receptor-1 gene and risk of Alzheimer's disease. , 2005, The journals of gerontology. Series A, Biological sciences and medical sciences.

[127]  Jonathan L Haines,et al.  Genetics, statistics and human disease: analytical retooling for complexity. , 2004, Trends in genetics : TIG.

[128]  L. Farrer,et al.  Regulatory region variability in the human presenilin-2 (PSEN2) gene: potential contribution to the gene activity and risk for AD , 2002, Molecular Psychiatry.

[129]  R. Tanzi,et al.  Clearance of Alzheimer's Aβ PeptideThe Many Roads to Perdition , 2004 .

[130]  W. McIntire,et al.  The G Protein β Subunit Is a Determinant in the Coupling of Gs to the β1-Adrenergic and A2a Adenosine Receptors* , 2001, The Journal of Biological Chemistry.

[131]  C. Caltagirone,et al.  Glutathione S-Transferase P1 *C Allelic Variant Increases Susceptibility for Late-Onset Alzheimer Disease: Association Study and Relationship with Apolipoprotein E ε4 Allele , 2005 .

[132]  T. Kita,et al.  Role of Oxidized LDL in Atherosclerosis , 2001, Annals of the New York Academy of Sciences.

[133]  Bosheng Zhang,et al.  Genetic studies of A2M and BACE1 genes in Chinese Han Alzheimer's disease patients , 2005, Neuroreport.

[134]  O. Combarros,et al.  Genetic interaction between two apolipoprotein E receptors increases Alzheimer's disease risk , 2006, Journal of Neurology.

[135]  D. Healy Case-control studies in the genomic era: a clinician's guide , 2006, The Lancet Neurology.

[136]  Mitsutoshi Yamamoto,et al.  A variant of the sigma receptor type-1 gene is a protective factor for Alzheimer disease. , 2005, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[137]  J. Ioannidis,et al.  Meta-analysis of the association of the cathepsin D Ala224Val gene polymorphism with the risk of Alzheimer's disease: a HuGE gene-disease association review. , 2004, American journal of epidemiology.

[138]  S. DeKosky,et al.  Association of 3′-UTR polymorphisms of the oxidised LDL receptor 1 (OLR1) gene with Alzheimer’s disease , 2003, Journal of medical genetics.

[139]  Thomas A Trikalinos,et al.  Genetic associations in large versus small studies: an empirical assessment , 2003, The Lancet.

[140]  W. Park,et al.  Choline acetyltransferase G +4 A polymorphism confers a risk for Alzheimer’s disease in concert with Apolipoprotein E ε4 , 2004, Neuroscience Letters.

[141]  M. Pearce,et al.  Gene–gene interaction in folate-related genes and risk of neural tube defects in a UK population , 2004, Journal of Medical Genetics.

[142]  E. Corder,et al.  Cystatin C as a risk factor for Alzheimer disease , 2005, Neurology.

[143]  C. Kumana,et al.  Association studies of genetic polymorphisms and complex disease , 2000, The Lancet.

[144]  C. Bell DSM-IV: Diagnostic and Statistical Manual of Mental Disorders , 1994 .

[145]  Marylyn D Ritchie,et al.  Renin-Angiotensin System Gene Polymorphisms and Atrial Fibrillation , 2004, Circulation.

[146]  O. Combarros,et al.  Interaction between Poly(ADP-Ribose) Polymerase 1 and Interleukin 1A Genes Is Associated with Alzheimer’s Disease Risk , 2007, Dementia and Geriatric Cognitive Disorders.

[147]  L. Feuk,et al.  Apolipoprotein-E dependent role for the FAS receptor in early onset Alzheimer's disease: finding of a positive association for a polymorphism in the TNFRSF6 gene , 2000, Human Genetics.

[148]  S. Sorbi,et al.  Insulin degrading enzyme and alpha-3 catenin polymorphisms in Italian patients with Alzheimer disease. , 2005, Alzheimer disease and associated disorders.

[149]  S. DeKosky,et al.  Investigation of oxidized LDL-receptor 1 (OLR1) as the candidate gene for Alzheimer's disease on chromosome 12 , 2002, Human Genetics.

[150]  W. Maier,et al.  Polymorphism in the BACE gene influences the risk for Alzheimer's disease , 2003, Neuroreport.

[151]  C. Plata-salamán,et al.  Inflammation and Alzheimer’s disease , 2000, Neurobiology of Aging.

[152]  G. Forloni,et al.  PEN–2 gene mutation in a familial Alzheimer’s disease case , 2005, Journal of Neurology.

[153]  J. H. Moore,et al.  Multifactor-dimensionality reduction shows a two-locus interaction associated with Type 2 diabetes mellitus , 2004, Diabetologia.

[154]  J. Haines,et al.  Association between bleomycin hydrolase and Alzheimer's disease in caucasians , 1998, Annals of neurology.

[155]  A. Quattrone,et al.  Increased risk for Alzheimer disease with the interaction of MPO and A2M polymorphisms. , 2004, Archives of neurology.

[156]  D. Cox,et al.  Additive and multiplicative models for the joint effect of two risk factors. , 2005, Biostatistics.

[157]  K. Ishii,et al.  Polymorphism of the regulatory region of the presenilin-2 gene in sporadic Alzheimer's disease: A case-control study , 2006, Journal of the Neurological Sciences.

[158]  S. DeKosky,et al.  Genetic variation in the cholesterol 24-hydroxylase (CYP46) gene and the risk of Alzheimer's disease , 2002, Neuroscience Letters.

[159]  A. Nunomura,et al.  Oxidative Damage Is the Earliest Event in Alzheimer Disease , 2001, Journal of neuropathology and experimental neurology.

[160]  Antonio S. Tutor,et al.  Polymorphism in genes involved in adrenergic signaling associated with Alzheimer’s , 2004, Neurobiology of Aging.

[161]  A. Soltanzadeh,et al.  Analysis of association between butyrylcholinesterase K variant and apolipoprotein E genotypes in Alzheimer's disease , 2004, Neuroscience Letters.

[162]  D. Goldstein,et al.  Association of genetic loci: Replication or not, that is the question , 2004, Neurology.

[163]  Onofre Combarros,et al.  Gene-gene interaction between interleukin-1A and interleukin-8 increases Alzheimer’s disease risk , 2004, Journal of Neurology.

[164]  B. Staels,et al.  Peroxisome proliterator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis , 1999 .

[165]  Dc Washington Diagnostic and Statistical Manual of Mental Disorders, 4th Ed. , 1994 .

[166]  S. Sorbi,et al.  Association of IL10 promoter polymorphism in Italian Alzheimer's disease , 2007, Neuroscience Letters.

[167]  B. Hyman,et al.  Role of the low-density lipoprotein receptor-related protein in beta-amyloid metabolism and Alzheimer disease. , 2000, Archives of neurology.

[168]  O. Combarros,et al.  The myeloperoxidase gene in Alzheimer's disease: a case-control study and meta-analysis , 2002, Neuroscience Letters.

[169]  S. DeKosky,et al.  No association of dynamin binding protein (DNMBP) gene SNPs and Alzheimer's disease , 2008, Neurobiology of Aging.

[170]  R. Petersen,et al.  Possible association between genetic variability at the apolipoprotein(a) locus and Alzheimer's disease in apolipoprotein E2 carriers , 2002, Neuroscience Letters.

[171]  Mitsutoshi Yamamoto,et al.  No association between the insulin degrading enzyme gene and Alzheimer's disease in a Japanese population , 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[172]  Shifts in angiotensin I converting enzyme insertion allele frequency across Europe: implications for Alzheimer’s disease risk , 2003, Journal of neurology, neurosurgery, and psychiatry.

[173]  D. Praticò,et al.  Lipid peroxidation and oxidative imbalance: early functional events in Alzheimer's disease. , 2004, Journal of Alzheimer's disease : JAD.

[174]  H. Soininen,et al.  Heparan sulfate proteoglycan 2 polymorphism in Alzheimer's disease and correlation with neuropathology , 2003, Neuroscience Letters.

[175]  Toshio Ogihara,et al.  α1‐Antichymotrypsin as a risk modifier for late‐onset Alzheimer's disease in Japanese apolipoprotein E ε4 allele carriers , 1997 .

[176]  P. Amouyel,et al.  Impact of the matrix metalloproteinase MMP-3 on dementia , 2007, Neurobiology of Aging.

[177]  S. Sevush,et al.  Association between Alzheimer's Disease and a Functional Polymorphism in the Myeloperoxidase Gene , 2001, Experimental Neurology.

[178]  K. Morgan,et al.  Microsatellite polymorphism of the α1-antichymotrypsin gene locus associated with sporadic Alzheimer’s disease , 1996, Human Genetics.

[179]  W. Maier,et al.  Polymorphism in the peroxisome proliferator-activated receptor α gene influences the risk for Alzheimer’s disease , 2003, Journal of Neural Transmission.

[180]  S. DeKosky,et al.  Bleomycin hydrolase is associated with risk of sporadic Alzheimer's disease , 1998, Nature Genetics.

[181]  B. Hyman,et al.  Neuronal expression of myeloperoxidase is increased in Alzheimer's disease , 2004, Journal of neurochemistry.

[182]  C. Dingwall,et al.  In search of an enzyme: the β-secretase of Alzheimer's disease is an aspartic proteinase , 2000, Trends in Neurosciences.

[183]  Zhenxin Zhang,et al.  Association analysis of brain-derived neurotrophic factor (BDNF) gene 196 A/G polymorphism with Alzheimer's disease (AD) in mainland Chinese , 2005, Neuroscience Letters.

[184]  R. Tanzi,et al.  Clearance of Alzheimer's Aβ Peptide The Many Roads to Perdition , 2004, Neuron.

[185]  D. Middleton,et al.  Association between polymorphism in regulatory region of gene encoding tumour necrosis factor α and risk of Alzheimer's disease and vascular dementia: a case-control study , 2001, The Lancet.